Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-026367
Filing Date
2019-10-30
Accepted
2019-10-30 19:52:22
Documents
2
Period of Report
2019-10-30

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3203
2 EX-24 DOCUMENT attachment1.htm EX-24 2327
  Complete submission text file 0000899243-19-026367.txt   6924
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE109 PRINCETON NJ 08540
Business Address
Lochner Daniel (Reporting) CIK: 0001791187 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39112 | Film No.: 191181590